Study Population
Cross-source consensus on Study Population from 1 sources and 5 claims.
1 sources · 5 claims
Evidence quality
Other
Other
Highlighted claims
- Eligible participants are adults at least 18 years old with histologically confirmed mucosal melanoma after R0 or R1 resection, ECOG 0 to 1, and M0 disease. — Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial
- Withdrawal can occur for newly confirmed distant metastasis after surgery, outside anticancer therapy, or participant choice. — Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial
- The study is limited by its single-arm, single-centre phase II design, modest sample size, and lack of stratified sample-size design by primary site. — Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial
- The study is not powered for site-specific comparisons and needs prospective validation in larger studies. — Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial
- The protocol’s strengths include a prospective design, clear eligibility criteria, uniform radiotherapy, fixed systemic therapy, and prespecified recurrence-free survival analysis. — Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial